China Universal Asset Management Co. Ltd. Has $10.25 Million Holdings in AstraZeneca PLC $AZN

China Universal Asset Management Co. Ltd. decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 10.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 133,580 shares of the company’s stock after selling 15,427 shares during the period. AstraZeneca makes up 0.8% of China Universal Asset Management Co. Ltd.’s holdings, making the stock its 23rd biggest holding. China Universal Asset Management Co. Ltd.’s holdings in AstraZeneca were worth $10,248,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. NewSquare Capital LLC grew its stake in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after purchasing an additional 218 shares during the period. Rakuten Investment Management Inc. acquired a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $31,000. FSA Wealth Management LLC increased its stake in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after acquiring an additional 376 shares in the last quarter. VSM Wealth Advisory LLC acquired a new position in shares of AstraZeneca during the 2nd quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after acquiring an additional 275 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AZN shares. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Citigroup initiated coverage on AstraZeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Barclays restated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Jefferies Financial Group initiated coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $103.00 price target on shares of AstraZeneca in a research note on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $208.76 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market cap of $323.77 billion, a PE ratio of 69.36, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The stock’s fifty day simple moving average is $122.11 and its two-hundred day simple moving average is $96.53. AstraZeneca PLC has a 1-year low of $122.48 and a 1-year high of $212.71.

AstraZeneca Announces Dividend

The firm also recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a dividend yield of 153.0%. AstraZeneca’s dividend payout ratio (DPR) is currently 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.